Car+ t cells genetically modified to eliminate expression of t-cell receptor and/or hla
AssigneeBoard of Regents, The University of Texas System
InventorsLaurence J. Neil Cooper, Hiroki Torikai
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
Claims37
An isolated in vitro T cell population wherein cells of the population comprise an endogenous T cell receptor coding sequence that is either not expressed or which encodes a nonfunctional T cell receptor and/or an endogenous HLA coding sequence that is either not expressed or which encodes a nonfunctional HLA;
- and a recombinant chimeric antigen receptor comprising an intracellular signaling domain, a transmembrane domain, and an extracellular domain comprising an antigen binding region.
Dependencies are inferred from the claim text.